secwatch.observer — SEC 8-K summary
======================================

Issuer:     Biomea Fusion, Inc. (BMEA)
CIK:        0001840439
Form:       8-K
Filed at:   2022-11-01T23:59:59+00:00
Accession:  0001193125-22-274908
Event type: other_material
Sentiment:  positive
Materiality: 0.60
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Biomea Fusion doses first T2D patient in Phase II of BMF-219; Phase I completed
-------------------------------------------------------------------------------

- First patient with type 2 diabetes dosed in Phase II portion of COVALENT-111 (Phase I/II) of BMF-219.
- Phase I healthy volunteer portion completed; BMF-219 well tolerated with favorable PK/PD profile.
- BMF-219 is the first menin inhibitor to reach clinic for type 2 diabetes; aims to restore beta cells.
- Initial Phase II data expected in first half of 2023; IND filing with FDA on track for Q4 2022.
- Preclinical data showed BMF-219 ability to restore beta cell mass in animal models of T2D.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1840439/000119312522274908/0001193125-22-274908-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1840439/000119312522274908/d350423d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-22-274908

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer